9-Propionylmaridomycin is a new macrolide antibiotic which is obtained by chemical modification of maridomycin obtained from the fermentation broth of Streptomyces hygroscopicus no. B-5050. The evaluation of maridomycin (MDM) derivatives, from several viewpoints, such as in vitro and in vivo antibacterial activities, blood levels, and subacute oral toxicities for 2 weeks, indicates that 9-propionylmaridomycin is the most effective compound among the tested derivatives (1).
This communication is mainly concerned with additional exploration of the in vitro antimicrobial activity of 9-propionylmaridomycin, such as antibacterial spectrum, sensitivity distribution of clinical isolates of staphylococci, influence of inoculum size, medium pH, and addition of serum during antibacterial activity, induction and development of bacterial resistance in vitro, cross resistance, bactericidal activity, and effect of pH in the aqueous solution on the antibacterial activity.
MATERIALS AND METHODS
Antibiotic used. 9-Propionylmaridomycin, which contains 9-propionylmaridomycin III as a main constituent, has been described earlier (1). The macrolide antibiotics used for reference were extracted from commercial preparations. Antibiotics were dissolved in a 1 mg/ml concentration in methanol and thereafter were diluted to a desirable concentration with distilled water.
Organisms used. Stock cultures used for testing the antibacterial nature of the antibiotic were maintained on Trypticase-soy-agar (TSA) (BBL) Bactericidal activity. The viability of the microorganism in the presence of the drug was determined by the standard microbial population count technique. An 18-h culture of S. aureus FDI 209 P was mixed with TSB in the ratio of 1/200 by volume, and the antibiotic was added to give a final concentration of 0.1, 1, 10, or 100 gg/ml. A sample was withdrawn immediately from each tube prior to incubation and at 2, 4, 6, and 8 h after incubation at 37 C. Platings were made in duplicate at several dilutions to insure a reliable count. Colony counts were made after 48 h of incubation.
RESULTS
Antibacterial spectrum. The antibacterial spectra of 9-propionylmaridomycin and other related macrolides against representative bacterial species are summarized in Table 1. 9-Propionylmaridomycin was active against gram-positive bacteria and weakly so against two gram-negative bacteria, such as Neisseria gonorrhoeae and Vibrio cholerae. The pattern of antibacterial activity of 9-propionylmaridomycin was nearly the same as that of josamycin and kitasamycin.
Influence of medium pH, inoculum size, and addition of serum. The MIC of 9-pro,pionylmaridomycin against three strains of S. aureus was determined with media of various pH. The antibacterial activity of the antibiotic against the test organisms was stronger at the alkaline pH than at neutral and acidic pH (Table 2). Similar results were reported earlier for at least one macrolide antibiotic, erythromycin (Abbott Laboratories, Scientific Division, No. Chicago, Ill. "Erythromycin," 1966, p. 14) . The same pattern of the change of antibacterial activity by medium pH was observed on josamycin and kitasamycin in the case of 9-propionylmaridomycin.
An increase in the MIC of the antibiotic against the test organisms was observed in proportion to the increase in inoculum size from 104 to 188 (Table 3) . A similar result was observed with the other macrolide antibiotics.
The addition of 10 to 50% horse serum to the medium did not influence the inhibitory activity of this antibiotic, nor did it inhibit that of related macrolide antibiotics.
Sensitivity distribution patterns of clinical isolates of S. aureus. Antibacterial activity of 9-propionylmaridomycin and macrolide antibiotics against clinical isolates of staphylococci was studied. 9-Propionylmaridomycin inhibited the growth of 41 of 91 strains tested at 3.125 ,ug/ml and 64 of 91 test strains (70.3%) at a concentration of 1.56 to 12.5 sg/ml of the antibiotic (Fig. 1) . Twenty-five of the 91 strains (27.5%) were not inhibited even at a concentration of 100 gg/ml of 9-propionylmaridomycin.
The distribution pattern of sensitivity was identical with that of josamycin and kitasamycin. Spiramycin and triacetyloleandomycin were less active in this respect than 9-propionylmaridomycin, and erythromycin was the most effective among the tested macrolide antibiotics. However, 41.8% (38 of 91) of the test strains were found resistant to erythromycin. These strains were classified in accordance with the report by Kono et al. (2) as follows: 25 strains, were classified into A group and were found to be highly resistant to all the test antibiotics including 9-propionylmaridomycin; 5 and 8 strains belonging to group B and C, respectively, were sensitive to josamycin and kitasamycin and were also sensitive to 9-propionylmaridomycin (Table 4) .
Induction of resistance. The resistanceinducing activity of 9-propionylmaridomycin was tested with S. aureus MS 537, a strain in which resistance is easily induced by erythromycin. The test organism was inoculated to TSB containing 9-propionylmaridomycin in concentrations of 0.01, 0.1, 1, and 10 ,ug/ml. One hour after incubation, a solution of 9-propionylmaridomycin was added to each tube, adjusting the concentration of the antibiotic to 50 gg/ml.
Upon further incubation, no bacterial growth was observed in the antibiotic-containing tubes. Similarly, no induction of resistance by 9-propionylmaridomycin was obtained when selected by erythromycin. When the cultures were induced by erythromycin and selected by erythromycin or 9-propionylmaridomycin, growth of S. aureus MS 537 was observed (Fig. 2) .
Development of resistance in vitro. The rate and degree of the resistance of S. aureus 209 P to 9-propionylmaridomycin and josamycin were nearly the same, and after the 10th to 15th transfer, the MIC of both antibiotics reached more than 400 ,g/ml (Fig. 3) .
Cross resistance. The presence of crossresistance between 9-propionylmaridomycin and each of five other macrolide antibiotics was studied with each of six artificially developed, highly-resistant mutants of S. aureus FDA 209 P. An intimate cross-resistance was observed among 9-propionylmaridomycin, josamycin, and kitasamycin, indicating the close resemblance of these three macrolide antibiotics, whereas the other three antibiotics showed somewhat different patterns of cross resistance (Table 5) . Bactericidal activity. The bactericidal activity of 9-propionylmaridomycin was compared with that of related macrolide antibiotics (Fig. 4) . When 9-propionylmaridomycin was added to the culture in a concentration of 0.1 ,ug/ml, the viable count of bacteria increased at the same degree as in the control culture. Although the tubes containing 1, 10, and 100 tsg of the antibiotic per ml showed neither an increase nor a marked decrease in the viable count of bacteria, a similar tendency was noted with the other macrolide antibiotics.
Effect of pH in solution. Solutions of the antibiotic at pH 4 (glycocoll-hydrochloride buffer), pH 7 (phosphate buffer), and pH 9 (glycocoll-sodium hydroxide buffer) were kept at 4 C, 37 C, and 100 C respectively, and the MIC against three strains of S. aureus was determined at various intervals.
The antibacterial activity of 9-propionylmaridomycin remained unchanged at 4 C after 14 days between pH 4 and 9. The activity of the antibiotic solutions at pH 4, 7, and 9 was not significantly affected by 72 h of treatment at 37 ANTIMICROB. AG. CHEMOTHER. Tables 6 and 7 show the effect of pH on the antibacterial activity of the antibiotic solution at 37 and 100 C, respectively. At pH 4 and 7, the antibiotic showed no loss of antibacterial activity by 30 min.
Josamycin, tested at same time in similar manner, showed results similar to those observed with 9-propionylmaridomycin. DISCUSSION Comparative in vitro studies described above revealed that 9-propionylmaridomycin was active against gram-positive bacteria and pathogenic Neisseriae, and its activity was stronger at alkaline pH than at neutral and acidic pH. The antibacterial activity of 9-propionylmaridomycin was not markedly influenced by the inoculum size nor by the presence of horse serum. By using artificially developed strains resistant against each of six macrolide antibiot- ics, including 9-propionylmaridomycin, a close cross resistance was observed between 9-propionylmaridomycin, josamycin, and kitasamycin. These three macrolide antibiotics and spiramycin were known to have sixteen-membered rings and are more closely related as a 1. Resistance-inducing activity of 9-propionylmaridomycin. (A) and (B) were induced by 9-propionylmaridomycin at concentrations of 0 (---,0.01 (----), 0.1 ( ---), I (-----_), and 10 ------) Asg/ml, and (C) and (D) were induced by erythromycin at concentrations of 0 (---) and 0.1 (---) JAg/ml. After 1 h of incubation, to (A) and (C) 9-propionylmaridomycin was added to a final concentration of 50 ,g/ml, and to (B) A most significant and desirable property of 9-propionylmaridomycin was lack of its ability to induce resistance in strains of staphylococci in which resistance is easily induced by erythromycin. It is possible that the ability to induce resistance in macrolide antibiotics is confined to 14-member ring antibiotics (erythromycin and oleandomycin) and that 16-membered antibiotics such as 9-propionylmaridomycin, josamycin, kitasamycin, and spiramycin lack this ability.
According to unpublished data from our laboratory, this substance has extremely low toxicity and is quite well absorbed by oral administration in experimental animals. These findings suggest that 9-propionylmaridomycin may be effective in vivo against gram-positive infections. 
